{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:52:08Z","timestamp":1777870328121,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-023-01642-8","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T06:04:07Z","timestamp":1683871447000},"page":"337-342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The rationale for intermittent administration of PTH in the management of mineral and bone disorder of chronic kidney disease"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-0016","authenticated-orcid":false,"given":"Michael","family":"Pazianas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"issue":"10225","key":"1642_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration (2020) Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395(10225):709\u2013733","journal-title":"Lancet"},{"key":"1642_CR2","unstructured":"Center for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2021, Atlanta, GA, 2021."},{"issue":"1","key":"1642_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11005\/jbm.2020.27.1.1","volume":"27","author":"M Pazianas","year":"2020","unstructured":"Pazianas M, Miller PD (2020) Current understanding of mineral and bone disorders of chronic kidney disease and the scientific grounds on the use of exogenous parathyroid hormone in its management. J Bone Metab 27(1):1\u201313","journal-title":"J Bone Metab"},{"issue":"11","key":"1642_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO) (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69(11):1945\u20131953","journal-title":"Kidney Int"},{"key":"1642_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/ki.1976.42","volume":"9","author":"HH Malluche","year":"1976","unstructured":"Malluche HH, Ritz E, Lange HP et al (1976) Bone histology in incipient and advanced renal failure. Kidney Int 9:355\u2013362","journal-title":"Kidney Int"},{"key":"1642_CR6","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1681\/ASN.2009121293","volume":"21","author":"M Wolf","year":"2010","unstructured":"Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21:1427\u20131435","journal-title":"J Am Soc Nephrol"},{"key":"1642_CR7","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1681\/ASN.2015020117","volume":"26","author":"T Isakova","year":"2015","unstructured":"Isakova T, Ix JH, Sprague SM et al (2015) Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol 26:2328\u20132339","journal-title":"J Am Soc Nephrol"},{"key":"1642_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters. Kidney Int 92:26\u201336","journal-title":"Kidney Int"},{"key":"1642_CR9","first-page":"Cd006023","volume":"8","author":"M Ruospo","year":"2018","unstructured":"Ruospo M, Palmer SC, Natale P et al (2018) Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev 8:Cd006023","journal-title":"Cochrane Database Syst Rev"},{"key":"1642_CR10","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1136\/bmj.282.6280.1919","volume":"282","author":"DE Memmos","year":"1981","unstructured":"Memmos DE, Eastwood JB, Talner LB et al (1981) Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J (Clin Res Ed) 282:1919\u20131924","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"Suppl 2","key":"1642_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/nep.13026","volume":"22","author":"ND Toussaint","year":"2017","unstructured":"Toussaint ND, Damasiewicz MJ (2017) Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms? Nephrology (Carlton) 22(Suppl 2):51\u201356","journal-title":"Nephrology (Carlton)"},{"key":"1642_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00223-015-0052-z","volume":"98","author":"EF Nemeth","year":"2016","unstructured":"Nemeth EF, Goodman WG (2016) Calcimimetic and calcilytic drugs: Feats, flops, and futures. Calcif Tissue Int 98:341\u2013358","journal-title":"Calcif Tissue Int"},{"key":"1642_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41581-018-0087-2","volume":"15","author":"M Vervloet","year":"2019","unstructured":"Vervloet M (2019) Renal and extrarenal effects of fibroblast growth factor 23. Nat Rev Nephrol 15:109\u2013120","journal-title":"Nat Rev Nephrol"},{"issue":"82","key":"1642_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-physiol-021119-034650","volume":"10","author":"J Musgrove","year":"2020","unstructured":"Musgrove J, Wolf M (2020) Regulation and effects of FGF23 in chronic kidney disease. Annu Rev Physiol 10(82):365\u2013390","journal-title":"Annu Rev Physiol"},{"issue":"10","key":"1642_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/ki.2010.281","volume":"78","author":"T Isakova","year":"2010","unstructured":"Isakova T, Wolf MS (2010) FGF23 or PTH: which comes first in CKD\u202f? Kidney Int 78(10):947\u2013949","journal-title":"Kidney Int"},{"issue":"12","key":"1642_CR16","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/jbmr.4155","volume":"35","author":"M Pazianas","year":"2020","unstructured":"Pazianas M, Miller PD (2020) The CKD-MBD syndrome: hysteresis in PTH involvement and PTH administration for its management. J Bone Miner Res 35(12):2313\u20132317","journal-title":"J Bone Miner Res"},{"key":"1642_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.kint.2015.12.004","volume":"89","author":"TB Dr\u00fceke","year":"2016","unstructured":"Dr\u00fceke TB, Massy ZA (2016) Changing bone patterns with progression of chronic kidney disease. Kidney Int 89:289\u2013302","journal-title":"Kidney Int"},{"issue":"11","key":"1642_CR18","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1210\/endo.138.11.5505","volume":"138","author":"H Dobnig","year":"1997","unstructured":"Dobnig H, Turner RT (1997) The effects of programmed administration of human parathyroid hormone fragment (1\u201334) on bone histomorphometry and serum chemistry in rats. Endocrinology 138(11):4607\u20134612","journal-title":"Endocrinology"},{"issue":"5","key":"1642_CR19","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1210\/en.2016-1451","volume":"158","author":"VM Knab","year":"2017","unstructured":"Knab VM, Corbin B, Andrukhova O, Hum JM, Ni P, Rabadi S, Maeda A, White KE, Erben RG, J\u00fcppner H, Christov M (2017) Acute parathyroid hormone injection increases C-terminal but not intact fibroblast growth factor 23 levels. Endocrinology 158(5):1130\u20131139","journal-title":"Endocrinology"},{"issue":"9","key":"1642_CR20","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1210\/jc.2012-1811","volume":"97","author":"ER Smith","year":"2012","unstructured":"Smith ER, Cai MM, McMahon LP, Holt SG (2012) Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 97(9):3357\u20133365","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1642_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1210\/jc.2009-1603","volume":"95","author":"T Shimada","year":"2010","unstructured":"Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Juppner H (2010) Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 95(2):578\u2013585","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1642_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2215\/CJN.06240611","volume":"7","author":"OM Gutierrez","year":"2012","unstructured":"Gutierrez OM, Smith KT, Barchi-Chung A, Patel NM, Isakova T, Wolf M (2012) (1\u201334) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. Clin J Am Soc Nephrol 7(1):139\u2013145","journal-title":"Clin J Am Soc Nephrol"},{"key":"1642_CR23","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1359\/jbmr.090406","volume":"24","author":"SM Burnett-Bowie","year":"2009","unstructured":"Burnett-Bowie SM, Henao MP, Dere ME, Lee H, Leder BZ (2009) Effects of hPTH(1\u201334) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res 24:1681\u20131685","journal-title":"J Bone Miner Res"},{"key":"1642_CR24","doi-asserted-by":"publisher","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299:F882-889","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"1642_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18(1):59\u201368","journal-title":"Osteoporos Int"},{"key":"1642_CR26","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.bone.2008.07.250","volume":"43","author":"EM Sebastian","year":"2008","unstructured":"Sebastian EM, Suva LJ, Friedman PA (2008) Differential effects of intermittent PTH(1\u201334) and PTH(7\u201334) on bone microarchitecture and aortic calcification in experimental renal failure. Bone 43:1022\u20131030","journal-title":"Bone"},{"key":"1642_CR27","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00198-016-3861-7","volume":"28","author":"M Ota","year":"2017","unstructured":"Ota M, Takahata M, Shimizu T et al (2017) Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. Osteoporos Int 28:1481\u20131490","journal-title":"Osteoporos Int"},{"issue":"9","key":"1642_CR28","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/jbmr.433","volume":"26","author":"Q Yuan","year":"2011","unstructured":"Yuan Q, Sato T, Densmore M, Saito H, Sch\u00fcler C, Erben RG, Lanske B (2011) FGF-23\/Klotho signaling is not essential for the phosphaturic and anabolic functions of PTH. J Bone Miner Res 26(9):2026\u20132035","journal-title":"J Bone Miner Res"},{"key":"1642_CR29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00223-010-9414-8","volume":"87","author":"M Sridharan","year":"2010","unstructured":"Sridharan M, Cheung J, Moore AE, Frost ML, Fraser WD, Fogelman I, Hampson G (2010) Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1\u201334) in postmenopausal osteoporosis: Association with biomarker of bone formation. Calcif Tissue Int 87:398\u2013405","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"1642_CR30","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/jbmr.4016","volume":"35","author":"DB Karpf","year":"2020","unstructured":"Karpf DB, Pihl S, Mourya S, Mortensen E, Kovoor E, Markova D, Leff JA (2020) A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults. J Bone Miner Res 35(8):1430\u20131440","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01642-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01642-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01642-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:20Z","timestamp":1777564400000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/2\/337\/8306244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["1642"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01642-8","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"4 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no relevant financial interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"For this type of study, formal consent is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}